Allergan looks to needle-free delivery for Botox

Allergan is looking to develop a needle-free formulation of Botox,  and it has signed a co-development deal with American Medical Systems  to use that company’s JetTouch platform.

Allergan got a urinary incontinence indication from the FDA in 2011, but only  for patients with neurological conditions like multiple sclerosis. The company  is hoping to expand the Botox market to include people with over-active  bladders, and AMS’ JetTouch may be just the platform to get it there.

JetTouch is a transdermal injection tech, delivering drugs without the use of  a needle to any area accessible endoscopically or percutaneously. AMS, which is  owned by Endo Pharmaceuticals ($ENDP),  doesn’t have FDA approval for the platform yet. The co-development deal  stipulates that AMS develop JetTouch for general use in the bladder, and then,  assuming Botox gets the expanded indication Allergan wants, seek approval for a  needle-free formulation of the drug.

Read the Full Article at http://www.fiercedrugdelivery.com/story/allergan-looks-needle-free-delivery-botox/2012-06-11

Source:  by Damian Garde on June 11, 2012 at http://www.fiercedrugdelivery.com/story/allergan-looks-needle-free-delivery-botox/2012-06-11